Anthera Pharmaceuticals Inc - ANTH - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Anthera Pharmaceuticals Inc - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
ANTH	Nasdaq	8731	http://www.anthera.com/	0.608 +0.028
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Anthera Pharmaceuticals Inc ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or - May 17th, 2013 6:37 am Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results - May 13th, 2013 3:22 pm ANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report - May 13th, 2013 7:01 am Q1 2013 ANTHERA PHARMACEUTICALS INC Earnings Release - After Market Close - May 13th, 2013 5:07 am Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study - May 7th, 2013 2:30 pm Anthera Announces First Quarter 2013 Financial Report and Conference Call - May 3rd, 2013 12:00 pm Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility - Apr 5th, 2013 3:45 pm ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material - Apr 5th, 2013 8:22 am ANTH's Blisibimod Enters Phase III - Apr 1st, 2013 4:03 pm ANTHERA PHARMACEUTICALS INC Financials - Mar 30th, 2013 11:04 am 4 Healthcare Stock Stories For Weekend Investment Wellness - Mar 28th, 2013 1:30 pm ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - Mar 28th, 2013 5:03 am Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod - Mar 27th, 2013 2:15 pm Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results - Mar 26th, 2013 2:15 pm ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or - Mar 26th, 2013 8:17 am ANTHERA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report - Mar 26th, 2013 7:34 am 4 Healthcare Stock Stories for Weekend Wellness - Mar 22nd, 2013 12:36 pm Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus - Mar 22nd, 2013 6:00 am ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events - Feb 25th, 2013 4:01 am SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Anthera Pharmaceuticals, Inc. in Connection with Executive Compensation - Feb 13th, 2013 9:47 am View All Current Headlines >>